Cholesteryl ester storage disease: Hepatopathology and effects of therapy with lovastatin

Authors

  • Adrian M. Di Bisceglie M.D,

    Corresponding author
    1. Liver Diseases Section, Digestive Diseases Branch, National Institute for Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892
    • Liver Diseases Section, Building 10, Room 4D 52, National Institutes of Health, Bethesda, MD 20892
    Search for more papers by this author
  • Kamal G. Ishak,

    1. Hepatic Pathology Department, Armed Forces Institute of Pathology, Washington, D. C. 20306
    Search for more papers by this author
  • Lionel Rabin,

    1. Hepatic Pathology Department, Armed Forces Institute of Pathology, Washington, D. C. 20306
    Search for more papers by this author
  • Jeffrey M. Hoeg

    1. Metabolic Diseases Section, National Heart, Lung and Bloud Institute, Bethesda, MD 20892
    Search for more papers by this author

Abstract

We describe three patients with cholesteryl ester storage disease. Diagnosis was confirmed by demonstrating a deficiency in lysosomal acid cholesteryl hydrolase activity in cultured skin fibroblasts from each of these patients. All had hepatomegaly, elevated serum aminotransferase activities and hyperlipoproteinemia. Histological examination of liver biopsy specimens before treatment revealed accumulation of fat within hepatocytes, bile duct epithelium and endothelial and Kupffer cells. Cholesterol crystals were recognized by their birefringence in frozen sections. A striking feature was the presence of markedly hypertrophied Kupffer cells and portal macrophages with foamy, tan-colored cytoplasm that stained readily with the periodic acid-Schiff reagent and aldehyde fuchsin. Periportal fibrosis was noted in all cases; incomplete cirrhosis was present in one case. Distinctive and hitherto undescribed lysosomal accumulations of triglyceride and cholesterol crystals were noted.

The patients were treated with lovastatin, a cholesterol-lowering agent, for at least 12 mo. No significant changes were seen in serum lipoprotein concentrations or liver histopathology after therapy. Thus lovastatin did not have an obviously beneficial effect on abnormal lipid metabolism in these patients.(HEPATOLOGY 1990; 11:764-772.)

Ancillary